Drugs / CHS-0214
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02486939 | Jul 2015 → Sep 2017 | psoriasis, rheumatoid arthritis | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02134210 | Jun 2014 → Jul 2015 | psoriasis | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02115750 | May 2014 → Oct 2015 | rheumatoid arthritis | Coherus Oncology, Inc. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-07-05 | Daiichi Sankyo | Daiichi Sankyo Announces Discontinuation of Etanercept Biosimilar (CHS-0214) Development in Japan daiichisankyo.com ↗ |
| 2014-08-18 | Daiichi Sankyo | Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody) daiichisankyo.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-0214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02486939 ↗ |
| Route | Subcutaneous | “50mg subcutaneous (Sc)” NCT02134210 ↗ |